Amicus Therapeutics and Blackstone Enter into $430 Million S

Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, announced that it has entered into a definitive agreement for a $430 million financing collaboration with funds managed by Blackstone (NYSE: BX). As part of the collaboration, Blackstone Life Sciences and Blackstone Credit have agreed to provide Amicus with a $400 million senior secured term loan facilitating a refinancin...

Related Keywords

Brad Colman , Simon Harford , Bradley Campbell , Twitter , Blackstone Life Sciences , Amicus Therapeutics , Linkedin , Blackstone Enter , Strategic Financing , Lower Cost , Improved Amortization , Amicus Common , Blackstone Credit , Chief Executive Officer , Craig Shepherd , Senior Managing Director , Amicus Chief Financial Officer , Life Sciences , Private Securities Litigation Reform Act , Annual Report , Press Release Image , Amicus , Herapeutics , Nasdaq , Gold , Lobal , Patient Dedicated , Biotechnology , Company , Ocused , Discovering , Developing , Elivering , Novel , Medicines , Mare , Diseases , Ntered , Efinitive , Agreement , 30 , Billion , Financing , Collaboration , Funds , Anaged , Blackstone , Yse , Sex , Life , Ciences , Credit , Greed , Rovide , 00 , Senior , Ecured , Term , Loan , Ffacilitating , Efinancin , Ebwire , Press Release , Ews Release ,